Target Name: FTOP1
NCBI ID: G100874223
Other Name(s): FTO pseudogene 1

FTOP1: A Drug Target / Disease Biomarker

FTOP1, also known as Fasorinib, is a drug target (or biomarker) that is being targeted for research in the field of cancer. It is a small protein that is found in various tissues throughout the body, including the brain, heart, and blood vessels.

Recent studies have shown that FTOP1 is highly expressed in various types of cancer, including breast, lung, and ovarian cancer. It has also been found to be associated with the development of cancer-related symptoms, such as pain, fatigue, and nausea.

One of the main reasons for the potential targeting of FTOP1 is its role in cell signaling. It is a key regulator of the NF-kappa-B signaling pathway, which is a controlling force in many cellular processes throughout the body. This signaling pathway is involved in the regulation of various cellular processes, including inflammation, DNA replication, and cell survival.

Research has shown that FTOP1 plays a crucial role in the regulation of NF-kappa-B signaling pathway. It helps to keep the signaling pathway in check, preventing it from getting out of control and leading to the development of cancer.

Another potential mechanism for the targeting of FTOP1 is its role in the regulation of cell growth. It has been shown to help regulate the growth and division of cancer cells, which is a key factor in their development and progression.

In addition to its role in cell signaling and cell growth, FTOP1 has also been shown to play a role in the regulation of inflammation. It has been found to be involved in the regulation of various immune cells, including T cells and macrophages, which play a crucial role in the immune system.

The high expression of FTOP1 in various types of cancer makes it an attractive drug target. Studies have shown that inhibiting its activity can lead to the regression of cancer cells and a reduction in their growth and spread. This suggests that FTOP1 could be an effective way to treat various types of cancer.

In conclusion, FTOP1 is a drug target (or biomarker) that has the potential to be a valuable tool in the fight against cancer. Its role in cell signaling, cell growth, and inflammation makes it an attractive target for research and development of new treatments. Further studies are needed to fully understand its potential and to determine its effectiveness in treating various types of cancer.

Protein Name: FTO Pseudogene 1

More Common Targets

FTSJ1 | FTSJ3 | FTX | FUBP1 | FUBP3 | FUCA1 | FUCA2 | Fucosyl GM1 | Fucosyltransferase | FUNDC1 | FUNDC2 | FUNDC2P2 | FUNDC2P3 | FUOM | FURIN | FUS | FUT1 | FUT10 | FUT11 | FUT2 | FUT3 | FUT4 | FUT5 | FUT6 | FUT7 | FUT8 | FUT8-AS1 | FUT9 | FUZ | FXN | FXR1 | FXR2 | FXYD1 | FXYD2 | FXYD3 | FXYD4 | FXYD5 | FXYD6 | FXYD6-FXYD2 | FXYD7 | FYB1 | FYB2 | FYCO1 | FYN | FYTTD1 | FZD1 | FZD10 | FZD10-AS1 | FZD2 | FZD3 | FZD4 | FZD4-DT | FZD5 | FZD6 | FZD7 | FZD8 | FZD9 | FZR1 | G protein-Coupled Inwardly-Rectifying Potassium Channel (GIRK) | G Protein-Coupled Receptor Kinases (GRKs) | G0S2 | G2E3 | G2E3-AS1 | G3BP1 | G3BP2 | G6PC1 | G6PC2 | G6PC3 | G6PD | GA-binding protein | GAA | GAB1 | GAB2 | GAB3 | GAB4 | GABA(A) receptor | GABARAP | GABARAPL1 | GABARAPL2 | GABARAPL3 | GABBR1 | GABBR2 | GABPA | GABPAP | GABPB1 | GABPB1-AS1 | GABPB1-IT1 | GABPB2 | GABRA1 | GABRA2 | GABRA3 | GABRA4 | GABRA5 | GABRA6 | GABRB1 | GABRB2 | GABRB3 | GABRD | GABRE | GABRG1